Evaluation of the Adequacy of Levothyroxine Replacement Therapy in Patients with Central Hypothyroidism1
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
As there are few data on the evaluation of the adequacy of levothyroxine (l-T4) therapy in patients with central hypothyroidism (CH), a prospective study was performed to assess the accuracy of various parameters in the follow-up of 37 CH patients. Total and free thyroid hormones, TSH, and a series of clinical and biochemical indexes of peripheral thyroid hormone action have been evaluated off and on l-T4 therapy. Samples were taken before the daily administration of l-T4. In all patients off therapy, clinical hypothyroidism and low levels of free T4 (FT4) were observed, whereas values of FT3, total T4, and total T3 were below the normal range in 73%, 57%, and 19% of cases, respectively. Most of the indexes of thyroid hormone action were significantly modified after l-T4 withdrawal and exhibited significant correlation with free thyroid hormone levels. During l-T4 replacement therapy, 32 patients had circulating levels of FT4 and FT3 and indexes within the normal range with a mean l-T4 daily dose of 1.5 ± 0.3 μg/kg BW. Despite normal serum FT4, 3 patients had borderline high values of FT3 and a clear elevation of serum-soluble interleukin-2 receptor concentrations, suggesting overtreatment. Low or borderline low FT4/FT3 levels indicated undertreatment in 2 patients. The clinical parameters lack the required specificity for the diagnosis or follow-up of CH patients. The l-T4 daily dose should be established, taking into account the weight, the age, and the presence of other hormone deficiencies or pharmacological treatment of CH patients. In conclusion, our results indicate that the diagnosis of CH is reached at best by measuring TSH and FT4 concentrations. In the evaluation of the adequacy of l-T4 replacement therapy, both FT4 and FT3 serum levels together with some biochemical indexes of thyroid hormone action are all necessary to a more accurate disclosure of over- or undertreated patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Manifestations of CeH are similar to those of primary hypothyroidism, but they can be masked by coexistent MPHD [1, 24, 25].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [24]
In the citing paper
“As in primary hypothyroidism [53], younger CeH patients require higher doses than the older ones [24, 25].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [24]
In the citing paper
“Overt CeH is most frequently indicated by the combined findings of low FT4 with low or normal TSH concentrations [24, 25].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [24]
In the citing paper
“Indeed, mean L-T4 daily doses of 1.2-1.6 μg/kg bw/day were judged sufficient in the large majority of adult CeH patients, with the main aim of achieving a more appropriate metabolic profile [24, 25, 55].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [24]
In the citing paper
“In particular, serum TSH concentrations are rapidly suppressed in a large portion of CeH patients during the administration of L-T4 [24, 25].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [24]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in PROP1 cause familial combined pituitary hormone deficiency
Wu, W., Cogan, J. D., Pfäffle, R. W., Dasen, J. S., Frisch, H., O'Connell, S. M., Flynn, S. E., Brown, M. R., Mullis, P. E., Parks, J. S., et al. (1998) · Nature Genetics · doi:10.1038/ng0298-147 · Cited by 568
Thyrotropin-Secreting Pituitary Tumors*
BECK-PECCOZ, P., BRUCKER-DAVIS, F., PERSANI, L., SMALLRIDGE, R. C., & WEINTRAUB, B. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-6-610 · Cited by 491
Self-citationEffects of thyroid hormones on bone and mineral metabolism
Mosekilde, L., Eriksen, E. F., & Charles, P. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30338-4 · Cited by 423
Levothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324
Beck-Peccoz, P., Amr, S., Menezes-Ferreira, M. M., Faglia, G., & Weintraub, B. D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504253121703 · Cited by 261 · cited 1×
“Restoration and maintenance of euthyroidism represent the therapeutic goals in CH. Specific therapies, such as oral TRH administration have been abandoned because of their cost and their restricted applicability to few patients with hypothalamic hypothyroidism ( 9 , 10).”
BackgroundSelf-citationThe Variable Clinical Phenotype in Thyroid Hormone Resistance Syndrome
BECK-PECCOZ, P., & CHATTERJEE, V. K. K. (1994) · Thyroid · doi:10.1089/thy.1994.4.225 · Cited by 231
Self-citationZelissen, P. M. J., Croughs, R. J. M., van Rijk, P. P., & Raymakers, J. A. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-3-199402010-00005 · Cited by 225
Collu, R., Tang, J., Castagné, J., Lagacé, G., Masson, N., Huot, C., Deal, C., Delvin, E., Faccenda, E., Eidne, K. A., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3918 · Cited by 207
Wood, A. J. J., & Toft, A. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407213310307 · Cited by 172
Hayashizaki, Y., Hiraoka, Y., Endo, Y., Miyai, K., & Matsubara, K. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08355.x · Cited by 152
Prevalence of Fractures in Postmenopausal Women with Thyroid Disease
SOLOMON, B. L., WARTOFSKY, L., & BURMAN, K. D. (1993) · Thyroid · doi:10.1089/thy.1993.3.17 · Cited by 149
Sawin, C. T., Herman, T., Molitch, M. E., London, M. H., & Kramer, S. M. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)91192-0 · Cited by 139
A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene.
Medeiros-Neto, G., Herodotou, D. T., Rajan, S., Kommareddi, S., de Lacerda, L., Sandrini, R., Boguszewski, M. C., Hollenberg, A. N., Radovick, S., & Wondisford, F. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118540 · Cited by 136
Thyrotropin-secreting pituitary tumors
Beck‐Peccoz, P. (1996) · Endocrine Reviews · doi:10.1210/er.17.6.610 · Cited by 131
Self-citationde Bruin, T. W. A., van Barlingen, H. H. J. J., Trip, M. D., de Vries, A.-R. V. D. V., Akveld, M. J., & Erkelens, D. W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.1.8421075 · Cited by 125
Dacou‐Voutetakis, C., Feltquate, D., Drakopoulou, M. I., KOURIDES, I. A., & Dracopoli, N. C. (1990) · PubMed · Cited by 117
The Use and Misuse of Thyroid Hormone*
Roti, E., Minelli, R., Gardini, E., & Braverman, L. E. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-401 · Cited by 115
Beck-Peccoz, P., Roncoroni, R., Mariotti, S., MEDRI, G., Marcocci, C., Brabant, G. E., Forloni, F., Pinchera, A., & Faglia, G. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-1-19 · Cited by 96
Self-citationDoeker, B. M., Pfäffle, R. W., Pohlenz, J., & Andler, W. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4780 · Cited by 62
Monitoring Therapy in Patients Taking Levothyroxine
Helfand, M., & Crapo, L. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-6-450 · Cited by 62
Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins
Pazos, F. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.2.562 · Cited by 59
Monitoring L-thyroxine therapy: Lessons from the effects of L-thyroxine on bone density
Ross, D. S. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90065-6 · Cited by 59
Bone mass in females with different thyroid disorders: influence of menopausal status
Campos-Pastor, M. M., Muñoz‐Torres, M., Escobar‐Jiménez, F., de Almodóvar, J. M. R., & Gimeno, E. J. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80115-8 · Cited by 51
A therapeutic controversy. Thyroid hormone treatment: when and what?
Oppenheimer, J. H. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.10.2873 · Cited by 49
Persani, L., Preziati, D., Matthews, C. H., Sartório, A., Chatterjee, K., & Beck‐Peccoz, P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2351057.x · Cited by 48
Self-citationSmallridge, R. C. (1983) · JAMA · doi:10.1001/jama.250.18.2489 · Cited by 44
Parks, J. S., Kinoshita, E., & Pfäffle, R. W. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90083-q · Cited by 27
The Fetus in Maternal Hyperthyroidism
PERELMAN, A. H., & Clemons, R. D. (1992) · Thyroid · doi:10.1089/thy.1992.2.225 · Cited by 22
Investigation and treatment of hypothyroidism
Lazarus, J. H. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.d01-1354.x · Cited by 19
Seppel, T., Becker, A. J., Lippert, F. K., & Schlaghecke, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.4.8636386 · Cited by 13
Koukkou, E. G., Panayiotidis, P. G., & Thalassinos, N. C. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03347809 · Cited by 9
Doeker, B. M., Pfaffle, R. W., Pohlenz, J., & Andler, W. (1998) · RWTH Publications (RWTH Aachen) · Cited by 7
Beck‐Peccoz, P., & MEDRI, G. (1988) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(88)80063-6 · Cited by 6
Self-citation
Research works printed but not linked: 5
- Collu, J Clin Endocrinol Metab, 82, 1561
- Beck-Peccoz, 1988, Congenital thyroid disease., In: Bailliere Clin Endocrinol Metab, 2, 737
- Mariotti, 1992, Thyroid function and thyroid autoimmunity indipendently modulate serum concentration of soluble interleukin 2 (IL2) receptor (sIL2R) in thyroid diseases., Clin Endocrinol (Oxf), 37, 417
- Pazos, J Clin Endocrinol Metab, 80, 562
- 1988, Osteoporosis: a growing concern for the thyroidologist., Thyroid Today, 11, 1
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Not only is serum TSH an unreliable indicator, but it may also become undetectable with small increments in LT4 that still leave the serum FT4 in the hypothyroid range (393).”
InfluentialHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges
Persani, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1616 · Cited by 295
Self-citationHigham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Metadata
- Authors
- Ferretti, E., Persani, L., Jaffrain-Rea, M.-L., Giambona, S., Tamburrano, G., & Beck-Peccoz, P.
- Affiliations
- University of L'Aquila (IT)
- University of Milan (IT)
- the Department of Experimental Medicine (E. F., M.-L.J.-R.), University of L’Aquila, L’Aquila, Italy
- Sapienza University of Rome (IT)
- Institute of Endocrine Sciences (L.P., S.G., P.B.-P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Auxologico Italiano IRCCS, and Istituto Clinico Humanitas, Milan
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-03-01
- Volume
- 84
- Issue
- 3
- Pages
- 924-929
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2096057448
- Cited by
- 134
- References
- 34
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 7
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Johnson and Johnson
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- central hypothyroidism, levothyroxine replacement therapy, treatment adequacy, free thyroxine, free triiodothyronine, thyroid-stimulating hormone, thyroid hormone action, soluble interleukin-2 receptor, overtreatment, undertreatment, dose adjustment
- MeSH terms
- Adult, Evaluation Studies as Topic, Female, Humans, Hypothyroidism, Male, Middle Aged, Prospective Studies, Thyroid Hormones, Thyroxine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.